2:10 PM
 | 
Nov 27, 2017
 |  BC Extra  |  Clinical News

Regeneron discontinues Eylea/nesvacumab combo

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said it will discontinue development of a fixed combination therapy comprising nesvacumab (REGN910) plus Eylea aflibercept to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD) after the combination "did not provide sufficient differentiation" from Eylea monotherapy in two Phase II trials.

The Phase II RUBY and ONYX trials compared nesvacumab plus Eylea, formulated as a single intravitreal injection, to...

Read the full 307 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >